194 related articles for article (PubMed ID: 23892627)
1. Optimization and regeneration kinetics of lymphatic-specific photodynamic therapy in the mouse dermis.
Kilarski WW; Muchowicz A; Wachowska M; Mężyk-Kopeć R; Golab J; Swartz MA; Nowak-Sliwinska P
Angiogenesis; 2014 Apr; 17(2):347-57. PubMed ID: 23892627
[TBL] [Abstract][Full Text] [Related]
2. Investigation of cell death mechanisms in human lymphatic endothelial cells undergoing photodynamic therapy.
Wachowska M; Osiak A; Muchowicz A; Gabrysiak M; Domagała A; Kilarski WW; Golab J
Photodiagnosis Photodyn Ther; 2016 Jun; 14():57-65. PubMed ID: 26868051
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of lymphangiogenesis impairs antitumour effects of photodynamic therapy and checkpoint inhibitors in mice.
Muchowicz A; Wachowska M; Stachura J; Tonecka K; Gabrysiak M; Wołosz D; Pilch Z; Kilarski WW; Boon L; Klaus TJ; Golab J
Eur J Cancer; 2017 Sep; 83():19-27. PubMed ID: 28709135
[TBL] [Abstract][Full Text] [Related]
4. Regression of mature lymphatic vessels in the cornea by photodynamic therapy.
Bucher F; Bi Y; Gehlsen U; Hos D; Cursiefen C; Bock F
Br J Ophthalmol; 2014 Mar; 98(3):391-5. PubMed ID: 24414403
[TBL] [Abstract][Full Text] [Related]
5. Photodynamic ablation of lymphatic vessels and intralymphatic cancer cells prevents metastasis.
Tammela T; Saaristo A; Holopainen T; Ylä-Herttuala S; Andersson LC; Virolainen S; Immonen I; Alitalo K
Sci Transl Med; 2011 Feb; 3(69):69ra11. PubMed ID: 21307301
[TBL] [Abstract][Full Text] [Related]
6. Photodynamic Therapy Leads to Time-Dependent Regression of Pathologic Corneal (Lymph) Angiogenesis and Promotes High-Risk Corneal Allograft Survival.
Hou Y; Le VNH; Clahsen T; Schneider AC; Bock F; Cursiefen C
Invest Ophthalmol Vis Sci; 2017 Nov; 58(13):5862-5869. PubMed ID: 29145577
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of Longitudinal Lymphatic Function Changes upon Injury in the Mouse Tail with Photodynamic Therapy.
Kuzminich Y; Dixon JB
Cardiovasc Eng Technol; 2023 Apr; 14(2):204-216. PubMed ID: 36403192
[TBL] [Abstract][Full Text] [Related]
8. Effect of tumor host microenvironment on photodynamic therapy in a rat prostate tumor model.
Chen B; Pogue BW; Zhou X; O'Hara JA; Solban N; Demidenko E; Hoopes PJ; Hasan T
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):720-7. PubMed ID: 15701861
[TBL] [Abstract][Full Text] [Related]
9. Drug and light dose responses to focal photodynamic therapy of single blood vessels in vivo.
Khurana M; Moriyama EH; Mariampillai A; Samkoe K; Cramb D; Wilson BC
J Biomed Opt; 2009; 14(6):064006. PubMed ID: 20059244
[TBL] [Abstract][Full Text] [Related]
10. Vascular-targeted low dose photodynamic therapy stabilizes tumor vessels by modulating pericyte contractility.
Cavin S; Riedel T; Rosskopfova P; Gonzalez M; Baldini G; Zellweger M; Wagnières G; Dyson PJ; Ris HB; Krueger T; Perentes JY
Lasers Surg Med; 2019 Aug; 51(6):550-561. PubMed ID: 30779366
[TBL] [Abstract][Full Text] [Related]
11. Disparity between prostate tumor interior versus peripheral vasculature in response to verteporfin-mediated vascular-targeting therapy.
Chen B; Crane C; He C; Gondek D; Agharkar P; Savellano MD; Hoopes PJ; Pogue BW
Int J Cancer; 2008 Aug; 123(3):695-701. PubMed ID: 18498134
[TBL] [Abstract][Full Text] [Related]
12. Selective photodynamic therapy by targeted verteporfin delivery to experimental choroidal neovascularization mediated by a homing peptide to vascular endothelial growth factor receptor-2.
Renno RZ; Terada Y; Haddadin MJ; Michaud NA; Gragoudas ES; Miller JW
Arch Ophthalmol; 2004 Jul; 122(7):1002-11. PubMed ID: 15249365
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the new photosensitizer Stakel (WST-11) for photodynamic choroidal vessel occlusion in rabbit and rat eyes.
Berdugo M; Bejjani RA; Valamanesh F; Savoldelli M; Jeanny JC; Blanc D; Ficheux H; Scherz A; Salomon Y; BenEzra D; Behar-Cohen F
Invest Ophthalmol Vis Sci; 2008 Apr; 49(4):1633-44. PubMed ID: 18385085
[TBL] [Abstract][Full Text] [Related]
14. Remodeling Lymphatic Vessels in Intrinsically Aged Skin on SKH-1 Mouse Using Low Dose 5-aminolevulinic Acid Photodynamic Therapy via VEGF-C/VEGFR3 Pathway.
Yang Y; Shen S; Cao Y; Wang D; Kang Z; Wang P; Wang X
Photodiagnosis Photodyn Ther; 2022 Jun; 38():102851. PubMed ID: 35398260
[TBL] [Abstract][Full Text] [Related]
15. 9-cis retinoic acid promotes lymphangiogenesis and enhances lymphatic vessel regeneration: therapeutic implications of 9-cis retinoic acid for secondary lymphedema.
Choi I; Lee S; Kyoung Chung H; Suk Lee Y; Eui Kim K; Choi D; Park EK; Yang D; Ecoiffier T; Monahan J; Chen W; Aguilar B; Lee HN; Yoo J; Koh CJ; Chen L; Wong AK; Hong YK
Circulation; 2012 Feb; 125(7):872-82. PubMed ID: 22275501
[TBL] [Abstract][Full Text] [Related]
16. Intracutaneous ALA photodynamic therapy: dose-dependent targeting of skin structures.
Sakamoto FH; Doukas AG; Farinelli WA; Tannous Z; Su Y; Smith NA; Zurakowski D; Anderson RR
Lasers Surg Med; 2011 Sep; 43(7):621-31. PubMed ID: 22057490
[TBL] [Abstract][Full Text] [Related]
17. EphrinB2-EphB4 signalling provides Rho-mediated homeostatic control of lymphatic endothelial cell junction integrity.
Frye M; Stritt S; Ortsäter H; Hernandez Vasquez M; Kaakinen M; Vicente A; Wiseman J; Eklund L; Martínez-Torrecuadrada JL; Vestweber D; Mäkinen T
Elife; 2020 Sep; 9():. PubMed ID: 32897857
[TBL] [Abstract][Full Text] [Related]
18. Targeting tissue factor on tumour cells and angiogenic vascular endothelial cells by factor VII-targeted verteporfin photodynamic therapy for breast cancer in vitro and in vivo in mice.
Hu Z; Rao B; Chen S; Duanmu J
BMC Cancer; 2010 May; 10():235. PubMed ID: 20504328
[TBL] [Abstract][Full Text] [Related]
19. Leukocyte-endothelial cell interaction is necessary for photodynamic therapy induced vascular permeabilization.
Debefve E; Mithieux F; Perentes JY; Wang Y; Cheng C; Schaefer SC; Ruffieux C; Ballini JP; Gonzalez M; van den Bergh H; Ris HB; Lehr HA; Krueger T
Lasers Surg Med; 2011 Sep; 43(7):696-704. PubMed ID: 22057497
[TBL] [Abstract][Full Text] [Related]
20. Defining the therapeutic window of vertebral photodynamic therapy in a murine pre-clinical model of breast cancer metastasis using the photosensitizer BPD-MA (Verteporfin).
Akens MK; Hardisty MR; Wilson BC; Schwock J; Whyne CM; Burch S; Yee AJ
Breast Cancer Res Treat; 2010 Jan; 119(2):325-33. PubMed ID: 19263216
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
